Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 5 | -$2.06 | $0.17 | -$0.63 |
Q2 2024 | 5 | -$2.32 | $0.19 | -$0.70 |
Q3 2024 | 5 | -$2.46 | $0.20 | -$0.75 |
Q4 2024 | 12 | -$1.02 | $0.57 | -$0.34 |
Q1 2025 | 6 | -$0.75 | -$0.34 | -$0.51 |
Q2 2025 | 5 | -$1.39 | $0.11 | -$0.42 |
Q3 2025 | 5 | -$1.22 | $0.10 | -$0.37 |
Q4 2025 | 5 | -$1.16 | $0.09 | -$0.35 |
Q1 2026 | 2 | -$0.87 | $0.07 | -$0.26 |
Q2 2026 | 2 | -$0.87 | $0.07 | -$0.26 |
Q3 2026 | 2 | -$0.87 | $0.07 | -$0.26 |
Q4 2026 | 2 | -$0.87 | $0.07 | -$0.26 |
Editas Medicine, Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $-0.75 earnings per share for the quarter, topping analysts' consensus estimates of $-0.76 by $0.01. The company had revenue of 61,000 for the quarter and had revenue of 78.12 M for the year. Editas Medicine, Inc. has generated $-2 earnings per share over the last year ($-2.02 diluted earnings per share) and currently has a price-to-earnings ratio of -0.47. Editas Medicine, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q3 2024 | -$0.76 | -$0.75 | 0.01 | $3.93 M | $61,000 |
08/07/2024 | Q2 2024 | -$0.69 | -$0.82 | -0.13 | $4.78 M | $513,000 |
05/08/2024 | Q1 2024 | -$0.63 | -$0.76 | -0.13 | $1.14 M | |
02/28/2024 | Q4 2023 | -$0.52 | -$0.23 | 0.29 | $60.05 M | |
11/03/2023 | Q3 2023 | -$0.64 | -$0.55 | 0.09 | $3.70 M | $5.34 M |
08/02/2023 | Q2 2023 | -$0.76 | -$0.56 | 0.2 | $4.17 M | $2.89 M |
05/05/2023 | Q1 2023 | -$0.79 | -$0.66 | 0.13 | $9.85 M | |
02/22/2023 | Q4 2022 | -$0.84 | -$0.80 | 0.04 | $6.54 M | |
11/02/2022 | Q3 2022 | -$0.87 | -$0.78 | 0.09 | $4.39 M | $42,000 |
08/03/2022 | Q2 2022 | -$0.84 | -$0.77 | 0.07 | $4.29 M | $6.36 M |
05/04/2022 | Q1 2022 | -$0.81 | -$0.74 | 0.07 | $6.77 M | |
02/24/2022 | Q4 2021 | -$0.78 | -$0.61 | 0.17 | $12.47 M | |
11/09/2021 | Q3 2021 | -$0.57 | $4.74 M | $6.20 M | ||
08/05/2021 | Q2 2021 | -$0.81 | $6.03 M | $379,000 | ||
05/06/2021 | Q1 2021 | -$0.86 | $6.50 M | |||
02/26/2021 | Q4 2020 | -$1.01 | $11.42 M | |||
11/06/2020 | Q3 2020 | $0.13 | $6.36 M | $62.84 M | ||
08/07/2020 | Q2 2020 | -$0.43 | $6.34 M | $10.75 M | ||
05/08/2020 | Q1 2020 | -$0.69 | $5.72 M | |||
02/26/2020 | Q4 2019 | $0.35 | -$0.74 | -1.09 | $12.28 M |
Editas Medicine, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, Editas Medicine, Inc. (:EDIT) reported $-0.75 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.76 by $0.01.
The conference call for Editas Medicine, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Editas Medicine, Inc.'s latest earnings report can be read online.
Editas Medicine, Inc. (:EDIT) has a recorded annual revenue of $78.12 M.
Editas Medicine, Inc. (:EDIT) has a recorded net income of $78.12 M. Editas Medicine, Inc. has generated $-2.02 earnings per share over the last four quarters.
Editas Medicine, Inc. (:EDIT) has a price-to-earnings ratio of -0.47 and price/earnings-to-growth ratio is 0.06.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED